Relatively low [18F]F-DED binding was observed in the patient with AD and who had evidence for the presence of β-amyloid and tau pathology (both assessed in CSF) and neurodegeneration as assessed by [18F]FDG–PET (A + T + N + ; Fig. 5; Additional file 1: Fig. S7). Here, MAPT is linked to Alzheimer disease.